Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
about
Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settingsChanges in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDSWhen to start antiretroviral therapy: as soon as possibleHIV protease inhibitors: a review of molecular selectivity and toxicityEfavirenz and the CNS: what we already know and questions that need to be answeredMonitoring HIV viral load in resource limited settings: still a matter of debate?Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-upMethodological standards in non-inferiority AIDS trials: moving from adherence to compliance.Efavirenz in the therapy of HIV infection.Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status.Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells.Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial dataDiscordance between viral loads determined by Roche COBAS AMPLICOR human immunodeficiency virus type 1 monitor (version 1.5) Standard and ultrasensitive assays caused by freezing patient plasma in centrifuged becton-dickinson vacutainer brand plasmaThe emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.Zidovudine and Lamivudine for HIV Infection.Impact of randomized antiretroviral therapy initiation on glucose metabolismLopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.The design and conduct of clinical trials to limit missing data.Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIVIs ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?Hypersensitivity reactions to HIV therapy.Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patientsChanges in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy.Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020AAtazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand.Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.Long-term treatment of patients with HIV-1: the role of atazanavirRelationships between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis.Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolismClinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE studyEfavirenz for HIV-1 infection in adults: an overview.Comparative effectiveness of efavirenz-based antiretroviral regimens in resource-limited settingsAtazanavir: the advent of a new generation of more convenient protease inhibitors.Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.
P2860
Q21144607-CB78DF6C-8A0A-46E2-9596-288D15F31C9CQ24792952-1E8FBC9A-35D2-48E2-B8B8-073FCADFBA8EQ27006767-AF11E650-E506-45B5-ACB6-FBCCE36C1497Q28082749-699151E8-768C-4271-8424-FC29A3773F95Q28085028-481D2356-91B9-414D-83DC-BA2169309D80Q28485511-6D3B03E5-CBBD-4495-95F6-31F5DC05A17CQ28538860-AD283D1F-D321-48EA-A94E-477C8EC01D89Q33258171-12BAE5F7-E159-4096-8C95-A194488259ABQ33607011-154F8456-46A7-41C8-99E2-36F48B3675E5Q33609481-8F9B3201-FDCD-46F7-A73F-335C3D301FE7Q33618645-9D33F491-5ACF-4703-967D-5698E685F540Q33891656-47A17F7E-BB77-4656-9DF9-D7F75C1A468AQ34042294-4F1D94EF-29D0-4A0D-B6ED-B5C84A75AB4EQ34102246-7B80B13C-97DE-4E73-9281-7E337478C428Q34134900-EF76B2A7-6771-472D-BB2D-F38D9D4ACA87Q34159702-D6D343EC-B49F-453C-9B86-C60291B40DECQ34194561-1055ABD9-490A-4DCC-ADA3-793F83BE1D63Q34205448-068A505C-445C-4D27-BFA4-B5E0E5BF1D0DQ34251223-3F5D545C-3F25-4398-9CAC-B9F03FA79624Q34350712-CE73A9A3-3222-4180-A9CA-BBF8C2A2FFF5Q34631149-6360B724-467A-4653-BB00-21F223E80A5DQ34727977-470FFDA1-C90B-45C8-AE7C-AB3FD2CCB3B5Q34854631-2A26318C-1F19-4A6F-BCD2-3B14E2BFE4E0Q34976463-F98C2C94-E9B1-4407-9F82-9723BE198A85Q35018821-04F5EF96-041C-4272-8612-1D457AD360B8Q35051199-2E114B58-CF20-498E-BB3B-BE103E48B580Q35163596-9BBA87D9-E5BA-47B2-88CE-4B6C4CA5B922Q35224956-78FE72F4-197C-49FA-A494-C46B720ED21CQ35288691-1ECCD40D-E3EB-4430-B3C6-465D026FBC6BQ35530299-E7A5114B-7837-4A99-A8F8-08F5F8313C50Q35547048-3CD5688C-94A2-42C3-AB84-AE993A9078C2Q35557219-B494AF78-C869-4C14-A182-80958EAC289DQ35630635-FCF6EAC5-0FA9-48EE-9FA3-A51D3B1431BDQ35674849-F3267FAB-159C-47C8-8F56-0109F071E35FQ35846917-AD0BEA6F-F40C-423E-87E3-1731DD5ACEC6Q35908862-65B4DAEC-D699-40F2-9819-8771AD6FC578Q35917519-A7448FE3-E2D9-44DB-A5CC-1784B93A89A8Q36031230-4BA04FCC-8D1E-4AFA-A2CC-3D225BA195B8Q36070100-2D8FDA74-CC13-4D13-92F6-8C6467ECA05CQ36094771-04C30FB3-BD23-4B6E-AE46-5B71C9C0797C
P2860
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Comparison of once-daily ataza ...... or patients infected with HIV.
@en
Comparison of once-daily ataza ...... or patients infected with HIV.
@nl
type
label
Comparison of once-daily ataza ...... or patients infected with HIV.
@en
Comparison of once-daily ataza ...... or patients infected with HIV.
@nl
prefLabel
Comparison of once-daily ataza ...... or patients infected with HIV.
@en
Comparison of once-daily ataza ...... or patients infected with HIV.
@nl
P2093
P50
P1476
Comparison of once-daily ataza ...... or patients infected with HIV.
@en
P2093
Alexandra Thiry
Antonio Rivero
Asda Vibhagool
Jean-François Delfraissy
Joseph Jemsek
José M Gatell
Kathleen Squires
Michael Giordano
Michael Sension
Shannon Schrader
P304
P356
10.1097/00126334-200408150-00003
P407
P577
2004-08-01T00:00:00Z